CompletedPhase 3

Cabergoline in Nonfunctioning Pituitary Adenomas

Brazil140 participantsStarted 2015-02-01

Plain-language summary

Clinically nonfunctioning pituitary adenoma remains the only pituitary tumor subtype for which no effective medical therapy is available or recommended. We will evaluate the use of cabergoline in a clinical trial, in order to define the efficacy of this treatment in nonfunctioning pituitary adenoma.

Who can participate

Age range18 Years – 75 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * presence of pituitary tumor rest at 6 months after neurosurgery * absence of previous hormonal pituitary hypersecretion * absence of previous radiotherapy and/or radiosurgery * Histopathological exam showing pituitary adenoma Exclusion Criteria: * ACTH immunoexpression at histopathological exam * presence of previous radiotherapy and/or radio surgery * psychotic psychiatric disease * moderate or severe alterations in cardiac valves

What they're measuring

tumor shrinkage

Timeframe: 24 months

Trial details

NCT IDNCT03271918

SponsorUniversity of Sao Paulo General Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2017-02-01

View on ClinicalTrials.gov More Pituitary Adenoma trials